Alpelisib
Estrogen-Receptor Positive Breast Cancer
Explore 74 assets in Estrogen-Receptor Positive Breast Cancer →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Jennifer Lee Caswell-Jin
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05101564CT.gov Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer | — | Completed | — | — | — |
NCT05508906CT.gov Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT01791478CT.gov BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT01219699CT.gov A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Estrogen-Receptor Positive Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Alpelisib (this asset) | Jennifer Lee Caswell-Jin | P2 | B · 62 |
| Exemestane | National Cancer Institute (NCI) | P4 | BBB |
| Everolimus | UNC Lineberger Comprehensive Cancer Center | P4 | BBB |
| Tamoxifen | Dana-Farber Cancer Institute | P4 | BB |
| Abemaciclib | Jonsson Comprehensive Cancer Center | P3 | BB |
| Palbociclib | Forward Pharmaceuticals Co., Ltd. | P3 | BB |
| Capivasertib | Imperial College London | P2 | BB |
| Giredestrant | Hoffmann-La Roche | P3 | BB |
| Ribociclib | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Estrogen-Receptor Positive Breast Cancer cohort
Other indications for Alpelisib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Triple-Negative Breast Carcinoma | — | P3 | BB · 67 |
| Breast Cancer | — | P4 | BB · 66 |
| HER2 Positive Breast Carcinoma | — | P3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Alpelisib in Estrogen-Receptor Positive Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/alpelisib-estrogen-receptor-positive-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →